The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Patients can now get the starting 2.5 mg dose for $299 per month
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Subscribe To Our Newsletter & Stay Updated
